Trial Profile
Phase II trial of vepoloxamer (MST-188) in patients with acute decompensated heart failure
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2017
Price :
$35
*
At a glance
- Drugs Poloxamer 188 (Primary)
- Indications Acute heart failure; Decompensated heart failure
- Focus Biomarker; Therapeutic Use
- Sponsors Mast Therapeutics; Savara Pharmaceuticals
- 11 Feb 2015 According to a Mast Therapeutics media release, is planning to initiate this Phase 2 study in the second quarter of 2015
- 09 Dec 2014 The US FDA has granted permission for the study to proceed, according to a Mast Therapeutics media release.
- 24 Oct 2014 New trial record